Predicting Endocrine Therapy Benefit in Early Stage Breast Cancer |
|
Overview
bioTheranostics has developed a two-gene index, Theros H/I,
that measures the expression of HOXB13 and IL17BR.
This index is used to stratify breast cancer patients
into high or low risk of recurrence, and predict
their ability to benefit from endocrine therapy.
- Theros H/I has been extensively studied and
clinically validated.1-7
- Theros H/I is a molecular biomarker for
endocrine benefit.4,5
- HOXB13 and IL17BR together measure
the functionality of the estrogen signaling
pathway in ER+ breast cancer.6
- Functional estrogen signaling (low H/I value)
predicts strong likelihood of benefit from
endocrine therapy.4,5
- Dysfunctional estrogen signaling
(high H/I value) predicts no benefit
from endocrine therapy.4,5
- High H/I values in the presence of rapid
proliferation as measured by Theros MGISM
(Molecular Grade Index) have been shown to
significantly increase recurrence risk.7
Link to publications |
Identifying Endocrine-Resistant,
ER+ Patients
In the U.S., approximately 115,000 women
per year are diagnosed with estrogen receptor
positive (ER+), node negative breast cancer.
A common dilemma for oncologists is
determining whether or not these patients
will benefit from endocrine therapy, as nearly
25% of patients treated with tamoxifen will
experience recurrence over 10-15 years.8
Theros H/I, a two-gene expression index,
provides information on both tumor
aggressiveness and predicts responsiveness
to endocrine therapy. Patients with a high
H/I value have a higher risk of endocrine
therapy failure and relapse. Theros H/I may
identify the majority of endocrine-resistant,
ER+ patients. |
References:
1 Ma, et al. A Two-Gene Expression Ratio Predicts Clinical Outcome in Breast
Cancer Patients Treated with Tamoxifen Cancer Cell 5:607-16, 2004.
2 Goetz, et al. A Two-Gene Expression of Homeobox 13 and Interleukin-17B
Receptor for Prediction of Recurrence and Survival in Women Receiving
Adjuvant Tamoxifen Clinical Cancer Research 12(7):2080-87, 2006.
3 Ma, et al. The HOXB13:IL17BR Expression Index is a Prognostic Factor in
Early-Stage Breast Cancer. Journal of Clinical Oncology, 24(28):4611-19, 2006.
4 Jansen, et al. Retrospective Study of the HOXB13-to-IL17BR Expression
Ratio Related to Tumor Aggressiveness and Response to Tamoxifen in
Recurrent Breast Cancer. Journal of Clinical Oncology, 25(6):662-668, 2007.
5 Jerevall, et al. Exploring the Two-Gene Ratio in Breast Cancer–Independent
Roles for HOXB13 and IL17BR in Prediction of Clinical Outcome. Breast
Cancer Research Treatment 102, April 2007.
6 Wang, et al. The Prognostic Biomarkers HOXB13, IL17BR and CHDH Are
Regulated by Estrogen in Breast Cancer. Clinical Cancer Research
13(21): 6327-6334, November 1, 2007.
7 Ma, et al. A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are
Complementary Prognostic Factors in Early Stage Breast Cancer. Clinical
Cancer Research 14(9): 2601-2608, May 1, 2008.
8 Fisher B, et al. Treatment of lymph-node negative, estrogen-receptor-positive
breast cancer: long-term findings from National Surgical Adjuvant Breast
and Bowel Project randomized clinical trials. Lancet. 2004; 364: 858-868.
9 Miao, et al. HOXB13 Promotes Ovarian Cancer Progression. Proc Nat Acad
Sci USA, 104:43, 17093-17098, 2006.
10 Sgroi, et al. Personal Communication, 2007.
11 Goldhirsch et al. Meeting highlights: International expert consensus on the
primary therapy of early breast cancer. Ann Oncology 16: 1569-1583, 2005.
| TOP |
|
